Search Bar & Filters
Found 12 Actively Recruiting clinical trials
Actively Recruiting
Chronic Inflammatory Demyelinating Polyradiculoneuropathy CIDP is an autoimmune disorder where the immune system attacks the protective covering of nerves, called myelin, leading to muscle weakness and loss of sensation in the arms and legs. This research is evaluating TAK-411, a modified immune globulin G made from human plasma, to see if it can reduce inflammation and improve symptoms in adults with CIDP. The main goal is to assess how TAK-411 affects physical functioning compared to a placebo group from a previous trial. Participants will receive TAK-411 through intravenous IV infusions. Initially, a 400 mgkg induction dose is given on Day 1, which may be repeated once after 3 weeks if no clinical change is seen. Following this, participants receive 200 mgkg IV infusions every 3 weeks for 24 weeks during the initial treatment period. Afterward, there is an optional extended treatment period lasting an additional 27 weeks. Participants may be treated with TAK-411 for up to 51 weeks and followed for 3 weeks after their last dose. During the study, participants may visit the clinic up to approximately 21 times. Various assessments will track functional ability and neurological status at multiple time points, including weeks 12, 24, and 54. Researchers will monitor changes using measures like the INCAT score, I-RODS score, hand grip strength, and adverse events. Safety and tolerability of TAK-411 will also be evaluated throughout the treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of ZL-1310 compared to the Investigators Choice Therapy in participants with relapsed small cell lung cancer SCLC. This phase 3 study aims to understand how well ZL-1310, a DLL3 antibody-drug conjugate, works against SCLC that has returned after initial treatment, with a focus on response rates and overall survival. Participants will receive either ZL-1310 as a single drug or Investigators Choice Therapy, which includes options like Topotecan or Amrubicin. The study is randomized and open-label, meaning participants are assigned to one of these treatments without masking. Treatment effects will be monitored over up to 30 months, with evaluations conducted regularly throughout this period. During the trial, participants will undergo tumor biopsies or provide archived tumor tissue samples at screening. They will be assessed for measurable disease and monitored for response using standard criteria RECIST v1.1, as well as quality of life measures. Safety will be tracked by recording treatment-related side effects and adverse events. The study includes comprehensive evaluations of survival, response duration, progression-free survival, and central nervous system responses, with participation lasting up to nearly three years.
Actively Recruiting
Researchers are studying telisotuzumab adizutecan, alone or combined with osimertinib, compared to standard care in adults with locally advanced or metastatic EGFR-mutated non-squamous non-small cell lung cancer NSCLC. The study aims to assess side effects and changes in disease activity over approximately 69 months, enrolling around 490 participants worldwide. This phase 23 open-label randomized trial evaluates treatment impact after progression on a third-generation EGFR tyrosine kinase inhibitor. In phase 2, participants receive one of two doses of telisotuzumab adizutecan through intravenous infusion either alone or with oral osimertinib. In phase 3, participants get the recommended phase 3 dose of telisotuzumab adizutecan or standard of care treatment. Treatments are allocated randomly, and the study includes multiple groups receiving different doses or combinations as part of the long study period. Participants will have regular visits at approved hospitals or clinics throughout the study. Researchers will monitor treatment effects through medical assessments, blood tests, questionnaires, and tracking side effects. Primary outcomes include objective response and progression-free survival assessed by independent review, while secondary outcomes measure overall survival, duration of response, disease control, and quality of life changes. The study carefully observes participants for up to approximately 69 months.
Actively Recruiting
Researchers are evaluating the pharmacokinetic comparability between TAK-881 and HYQVIA when given as subcutaneous injections for maintenance therapy in adults with chronic inflammatory demyelinating polyradiculoneuropathy CIDP. This phase 3 trial focuses on participants who have been receiving intravenous or subcutaneous immunoglobulin treatments and aims to compare these two treatments in terms of how the body absorbs and processes them. The study includes several phases starting with screening and possibly a ramp-up phase for those switching treatments. Participants already on HYQVIA go directly to that treatment phase, which lasts 18 to 20 weeks depending on dosing intervals. Then all participants switch to TAK-881 for 24 weeks. After this, an extension phase allows continued treatment for up to 3 years, with home infusions permitted and clinic visits spaced between 12 and 24 weeks. Treatments are given by subcutaneous infusion using specialized needle sets. Participants will visit the clinic every 3 or 4 weeks during the initial phases to undergo assessments including blood sampling to measure immunoglobulin G levels at various time points. The study also tracks clinical disability scores, hand grip strength, muscle strength, and adverse events over time. Safety and treatment tolerability are closely monitored throughout the trial. Total participation may last several years including the extension phase.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of Staccato alprazolam, an inhaled medication, in people aged 12 years and older who experience stereotypical prolonged seizures. The study aims to compare a single dose of Staccato alprazolam with a placebo in quickly stopping a seizure within 90 seconds and preventing further seizures for up to 2 hours after treatment. Participants are randomly assigned to receive either one dose of Staccato alprazolam or a matching placebo by inhalation in this double-blind study. This single-dose treatment is given during the outpatient treatment period, and participants are monitored closely to assess seizure control and safety. During the study, participants will have their seizures evaluated for treatment success within 90 seconds and for any recurrence up to 6 hours after dosing. Researchers will also monitor respiratory events and seizure frequency. Participants will have regular assessments, including safety follow-up visits extending up to 19 weeks after treatment, to ensure thorough monitoring of effects and any adverse events.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the FastWire System in patients who have chronic total occlusions CTOs in the arteries of their lower limbs. This study focuses on patients with severe leg ischemia caused by these blockages, aiming to see if the FastWire System can help place guidewires or treatment devices through these total artery blockages. The trial is a single-arm, multi-center pivotal study involving up to 65 participants with specific artery conditions. Participants will undergo treatment using the FastWire System, a device intended to assist during the procedure by crossing chronic total occlusion caps or multiple lesions in the peripheral arteries below the superficial femoral artery. The treatment is performed during a single procedure, with the goal of facilitating intra-luminal placement of wires or devices through the blocked arteries. This is an interventional study focused on treatment with no comparison group. During the study, participants will be monitored closely on the day of the procedure and up to 30 days afterward. Researchers will evaluate clinical and technical success on the procedure day, freedom from serious adverse events up to 30 days, vessel dissection or bleeding shortly after the procedure, and procedure-related mortality within 7 and 30 days. Participants will have assessments related to safety and effectiveness, including imaging and clinical evaluations, to measure the outcomes of the FastWire System treatment.
Actively Recruiting
Researchers are evaluating the efficacy and safety of Imeroprubart in adults with active Chronic Inflammatory Demyelinating Polyneuropathy CIDP, a neurological disorder. This Phase 2b, multi-center, randomized, double-blind, placebo-controlled study focuses on adult participants who meet specific diagnostic criteria for CIDP or its variants. The study is sponsored by Immunovant Sciences GmbH and aims to understand how well Imeroprubart helps prevent relapses and improves disability and muscle strength in this population. Participants will receive either Imeroprubart or a matching placebo by subcutaneous injection once weekly. The initial treatment period lasts 24 weeks, with a further extension period of 52 weeks for continued evaluation. Imeroprubart is given as a dose 1 injection under the skin weekly during these periods, while the placebo group receives matching injections during the first 24 weeks. Throughout the study, participants will be regularly assessed for relapse status, disability scales, grip strength, muscle strength scores, and functional impairment from baseline up to Week 24. These assessments include standardized clinical scales such as the Inflammatory Rasch-Built Overall Disability Scale I-RODS and Medical Research Council Sum Score MRC-SS. Safety and efficacy are closely monitored, with the primary outcome focusing on the proportion of participants remaining relapse-free by Week 24. The total study duration extends until May 2030.
Actively Recruiting
Researchers are conducting the FLEX Registry, a large-scale, population-based study focusing on patients with stage I to III breast cancer who have undergone MammaPrint and BluePrint testing on their primary breast tumors. This observational registry aims to gather comprehensive full genome expression data linked with clinical information to explore new gene associations that may have prognostic or predictive value. The design is adaptive, allowing additional targeted substudies and arms to be added over time for more specific investigations. All participants will have their tumor samples tested using MammaPrint and BluePrint through the full-genome testing array provided by Agendia. Treatment decisions are made by the treating physician following NCCN guidelines or recognized alternatives, with no specific treatment mandated by the study. The registry plans to enroll about 30,000 patients from more than 125 US institutions, encompassing various treatment arms detailed in study appendices. Participants will have clinical data collected online at multiple time points at enrollment, during treatment, and at 1, 3, 5, and 10 years after diagnosis. This long-term follow-up allows researchers to study gene expression alongside clinical outcomes, supporting the creation of subgroup analyses and future targeted trials. The primary outcomes include establishing a large-scale full genome expression registry and providing infrastructure for examining smaller patient groups over the 10-year study period.
Actively Recruiting
This research aims to evaluate the Velocity Percutaneous Arteriovenous Fistula pAVF System, a new minimally invasive device designed to create dialysis access for adults with kidney failure who require hemodialysis. Traditional arteriovenous fistula AVF creation involves surgery, which can require incisions, longer recovery, and additional procedures. This study will assess the safety and effectiveness of the Velocity System, which creates an AVF through a small skin puncture without open surgery. All participants will undergo AVF creation using the Velocity pAVF device via a catheter-based procedure. After the procedure, participants will be followed closely with physical exams, ultrasound scans, and dialysis evaluations to monitor fistula maturation, usability for hemodialysis, and long-term function. Additional procedures to assist fistula maturation or maintain access function will be recorded. Safety monitoring will include tracking device-related and procedure-related complications. Participants will be involved in regular assessments over up to five years, including physiologic and functional maturation checks, hemodialysis timing, catheter use, and fistula patency evaluations. Researchers will measure outcomes such as device success, adverse events, and the need for reinterventions. This long-term follow-up aims to provide comprehensive information about the performance and safety of the Velocity pAVF system in people with kidney failure.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a new drug called daraxonrasib compared to the chemotherapy drug docetaxel in patients with non-small cell lung cancer NSCLC who have specific RAS gene mutations and have already received treatment. This global, randomized, open-label Phase 3 study aims to find out if daraxonrasib can improve how long patients live without their cancer worsening or overall survival compared to standard chemotherapy. Participants are randomly assigned to one of two groups one group receives daraxonrasib as oral tablets, and the other group receives docetaxel through intravenous infusion. The study follows patients over several years to compare the outcomes of these treatments. Patients receive treatment according to their assigned group and are monitored regularly throughout the study period. During the study, participants will have assessments including scans to measure tumor size, tests to check organ function, and questionnaires about quality of life. Researchers will evaluate progression-free survival and overall survival as main outcomes, along with the safety and tolerability of the treatments. The study lasts up to approximately four years, with ongoing monitoring of patients health and treatment responses.
1-10 of 12
1